Aicar. AICA R. Aica Ribonucleotide. With many different names for the same solution, you may need to search them all to find information about what you’re looking for. We like to go by Aicar when we’re marketing our product for research purposes. Typically coming in 50mg bottles, Aicar is manufactured and sold as an analog of adenosine monophosphate, or AMP. Most researchers look to acquire Aicar because of the hand AMP analogs have been dealt.
AMP is either converted to adenosine pyrophosphate, the most important compound in metabolism, or adenosine triphosphate, the source of chemical energy needed to drive most living cells! Analogs are what we use to help dictate what we want the AMP to turn in to and why.
Documented Clinical Use
With many of the products that we choose to write about, there is a lack of research history to support strong proclamations of use. That isn’t really the case with Aicar. Already widely accepted and well regarded as a way to “treat and protect against cardiac ischemic injury,” Aicar studies have been marching toward the unknown. The three or four years have been really exciting. New technology has allowed scientists to delve deeper into the potential uses for Aicar.
- In Spring of 2016, a team of scientists in South Korea started to investigate the role of AMP-activated protein kinase in rats with cholestasis. (Any condition in which substances normally excreted into stomach bile are retained)
- By late 2016, a group of Japanese scientists decided to work off the information the earlier team published and moved on to a different organ; The liver. They proved that it was possible to use Aicar to leverage AMP activated protein kinase, or AMPK, to help improve ethanol-induced liver injuries.
- February 1st, 2017. More work being done across seas. Mice undergo a stage of hepatic lipid accumulation because of AMP’s upregulation of fatty acid.
- February 5th, 2017. Another team starts to experiment with modulating AMP/AMPK, using Aicar as an analog or conduit. The rats used in the research showed that altering the AMPK makeup and levels could be “the potential mechanism responsible for the regulation of testis function and differentiation following NP exposure.”
- By the end of 2017, research was being completed investigating the potential for treatment of NAFLD, or non-alcoholic fatty liver disease.
Future of Aicar in Research
It’s safe to say that AMP is going to be heavily studied, utilized, and modified over the next decade. Even more recent studies yield promising results when using AMP-based modifiers for liver disease treatment and even in some cancer research studies. While scientists in labs around the world look for new effective ingredients for safe medicinal purposes, research groups will be needing a whole lot of quality Aicar to get their end-result AMP. We understand the importance of quality and ensure you’ll get it with our 100% made in the USA product line.
1 Li, X, et al. “Role of AMP-Activated Protein Kinase α1 in 17α-Ethinylestradiol-Induced Cholestasis in Rats.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, Jan. 2017, www.ncbi.nlm.nih.gov/pubmed/27090119.
2 Yang, Y, et al. “Upregulation of SIRT1-AMPK by Thymoquinone in Hepatic Stellate Cells Ameliorates Liver Injury.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, 16 Nov. 2016, www.ncbi.nlm.nih.gov/pubmed/27688165.
3 Choi, Y J, et al. “Activation of AMPK by Berberine Induces Hepatic Lipid Accumulation by Upregulation of Fatty Acid Translocase CD36 in Mice.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, 1 Feb. 2017, www.ncbi.nlm.nih.gov/pubmed/28038998.
4 Duan, P, et al. “4-Nonylphenol Induces Autophagy and Attenuates MTOR-p70S6K/4EBP1 Signaling by Modulating AMPK Activation in Sertoli Cells.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, 5 Feb. 2017, www.ncbi.nlm.nih.gov/pubmed/28041982.
5 Zhang, J, et al. “Baicalin Protects AML-12 Cells from Lipotoxicity via the Suppression of ER Stress and TXNIP/NLRP3 Inflammasome Activation.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, 25 Dec. 2017, www.ncbi.nlm.nih.gov/pubmed/29031535.